Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a decision expected by June 2025. The FDA accepted the supplemental biologics ...

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...

ASSAGAO: In a latest development to the Oxel Spring case, the officials from Town and Country Planning and Land Survey Department remained conspicuous by their absence during the site inspection on ...

Evaluating the efficacy of cabozantinib in patients with advanced renal cell carcinoma with bone metastasis: An open-label phase 2 study. This is an ASCO Meeting Abstract from the 2025 ASCO ...